79 related articles for article (PubMed ID: 1988123)
1. Phase I trial of natural human interferon beta in metastatic malignancy.
Bukowski RM; Sergi JS; Sharfman WJ; Budd GT; Murthy S; Barna B; Medendorp SV; Yen-Lieberman B; Gibson V; Bauer L
Cancer Res; 1991 Feb; 51(3):836-40. PubMed ID: 1988123
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
9. Extended phase I study of human beta-interferon in human cancer.
Abdi EA; Kamitomo VJ; McPherson TA; Konrad MW; Inoue M; Tan YH
Clin Invest Med; 1986; 9(1):33-40. PubMed ID: 3955919
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of recombinant beta-interferon given by four-hour infusion.
Grunberg SM; Kempf RA; Venturi CL; Mitchell MS
Cancer Res; 1987 Feb; 47(4):1174-8. PubMed ID: 3802098
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of weekly high-dose human lymphoblastoid interferon.
Connors JM; Silver HK
Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
[TBL] [Abstract][Full Text] [Related]
15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon.
Green MD; Speyer JL; Hochster HS; Liebes LF; Dunleavy S; Widman T; Wernz JC; Blum RH; Spiegel RJ; Muggia FM
Cancer Res; 1988 May; 48(9):2574-8. PubMed ID: 3356017
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of Wellferon (human lymphoblastoid alpha-interferon) as cancer therapy: clinical results.
Sarna G; Figlin R; McCarthy S
J Biol Response Mod; 1983; 2(2):187-95. PubMed ID: 6644335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]